How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/rheumatoid-arthritis-in-patient-at-high-ulcer-risk.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rheumatoid Arthritis in Patient at High Ulcer Risk — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rheumatoid Arthritis in Patient at High Ulcer Risk (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Rheumatoid Arthritis in Patient at High Ulcer Risk, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Nexium	esomeprazole	AstraZeneca	Proton pump inhibitor (PPI)	Potassium-transporting ATPase	2001-02-20
Cytotec	misoprostol	Generic (originally Searle/Pfizer)	Prostaglandin E1 analog	Prostaglandin E2 receptor EP2 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin E2 receptor EP4 subtype	1988-12-27
Voltaren	DICLOFENAC	Hisamitsu Pharmaceutical Co., Inc	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	1988-01-01
Arthrotec	Diclofenac Sodium	Pfizer	diclofenac	Acid-sensing ion channel 3	1988-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Rheumatoid Arthritis in Patient at High Ulcer Risk
AstraZeneca · 1 drug in Rheumatoid Arthritis in Patient at High Ulcer Risk
Generic (originally Searle/Pfizer) · 1 drug in Rheumatoid Arthritis in Patient at High Ulcer Risk
Hisamitsu Pharmaceutical Co., Inc · 1 drug in Rheumatoid Arthritis in Patient at High Ulcer Risk

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Rheumatoid Arthritis in Patient at High Ulcer Risk:

Cite this brief

Drug Landscape (2026). Rheumatoid Arthritis in Patient at High Ulcer Risk — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/rheumatoid-arthritis-in-patient-at-high-ulcer-risk. Accessed 2026-06-10.

Rheumatoid Arthritis in Patient at High Ulcer Risk full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing